Stemline Therape buy melinda
Startpreis
10.08.18
/
50%
13,53 €
Kursziel
29.08.18
15,06 €
Rendite (%)
11,33 %
Endpreis
29.08.18
15,06 €
Zusammenfassung
Diese Einschätzung wurde am 29.08.18 mit einem Endkurs von 15,06 € beendet. Die Einschätzung konnte insgesamt eine Rendite von 11,33 % verzeichnen. melinda hat 50% Zuversicht bei dieser Einschätzung
Finanztrends
Rendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| Stemline Therape | - | - | - | - |
| iShares Core DAX® | -1.586% | 5.028% | 6.332% | 64.061% |
| iShares Nasdaq 100 | -4.148% | -0.125% | 25.735% | 86.918% |
| iShares Nikkei 225® | -6.302% | 0.528% | 41.384% | 77.872% |
| iShares S&P 500 | -3.225% | 0.470% | 20.449% | 68.192% |
Kommentare von melinda zu dieser Einschätzung
In der Diskussion Stemline Therape diskutieren
SecteurRecherche biotechnologique et médicale Agenda 14/11 Publication de résultats
Engages in the discovering, acquiring, developing and commercializing proprietary therapeutics
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need.
Its clinical stage product candidates include SL-401, SL-801, and SL-701.
The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies.
The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in a solid and hematologic malignancies.
The SL-701, is an immunotherapy designed to activate the immune system to attack tumors.
The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need.
Its clinical stage product candidates include SL-401, SL-801, and SL-701.
The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies.
The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in a solid and hematologic malignancies.
The SL-701, is an immunotherapy designed to activate the immune system to attack tumors.
The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.
Nombre d'employés : 37 personnes.
(Zielkurs erreicht)